VIDEO: Pegcetacoplan shows increased treatment benefit at 2 years
CHICAGO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, shares data from the DERBY and OAKS trials assessing pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
“Through 2 years in the phase 3 global OAKS and DERBY program involving over 1,200 patients, we’re seeing an increasing treatment benefit that is consistent over time with pegcetacoplan, we’re seeing a fascinating microperimetry signal that is showing preservation of visual function with preservation of photoreceptor cells, and finally, we saw a manageable safety profile with an increased rate of wet AMD,” Wykoff said.
Collapse
Wykoff CC. Treatment of geographic atrophy secondary to AMD with pegcetacoplan: Two-year outcomes from the randomized phase 3 DERBY and OAKS trials. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.
Read more about